---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-106240"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-12-06T23:59:59+00:00"
generated_at: "2026-05-29T06:45:59.741518+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics appoints Chris Ehrlich as permanent CEO

## Summary
- Chris Ehrlich appointed permanent CEO effective Dec 2, 2024, was interim since Oct 2.
- Company plans to file IND for CER-1236 in solid tumors (ovarian, NSCLC) in H1 2025.
- Ehrlich also serves as CEO of Launch One Acquisition Corp.
- Ehrlich brings biotech leadership experience including prior SPAC mergers and venture capital.

## SEC filing metadata
- accession: 0001213900-24-106240
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/0001213900-24-106240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/ea0223559-8k_cerotherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-106240
- JSON: https://secwatch.observer/filing/0001213900-24-106240.json
- Plain text: https://secwatch.observer/filing/0001213900-24-106240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.